EP300 Cancer Research Results

EP300, E1A binding protein p300: Click to Expand ⟱
Source: CGL-Driver Genes
Type: TSG (actually onocogene)
A transcriptional co-activator that plays a crucial role in regulating gene expression, cell growth, and differentiation. It is involved in various cellular processes, including the response to signaling pathways and the regulation of the cell cycle.
EP300 functions as a tumor suppressor in some contexts, while in others, it may promote oncogenic processes. Its role can depend on the specific type of cancer and the molecular context.
High levels may correlate with poor survival outcomes.
EP300 is a critical player in cancer biology, with its expression levels serving as potential biomarkers for prognosis in various cancers. Its role in transcriptional regulation and chromatin remodeling underscores its importance in tumorigenesis and cancer progression.

EP300 (p300) encodes a histone acetyltransferase (HAT) and transcriptional co-activator. p300 acetylates histones (e.g., H3, H4) and numerous non-histone proteins, loosening chromatin and enabling transcription. It functions as a signal integrator, translating upstream cues (growth factors, stress, hypoxia) into gene expression programs.
Key Pathways Modulated by EP300
Pathway / TF	           EP300 Effect	                Cancer Consequence
p53	                   Acetylation → activation	Tumor suppression (when intact)
MYC	                   Co-activation	        Proliferation, metabolism
HIF-1α	                   Co-activation under hypoxia	Angiogenesis, survival
NF-κB	                   Acetylation	                Inflammation, survival
Hormone receptors (ER/AR)  Co-activation	        Lineage-specific growth


Scientific Papers found: Click to Expand⟱
100- QC,    Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4/6↓, E2Fs↓, PCNA↓, cDC2↓, PTEN↑, MSH2↑, P21↑, EP300↑, BRCA1↑, NF2↑, TSC1↑, TGFβR1↑, P53↑, RB1↑, AKT1↓, cMyc↓, CDC7↓, cycF↓, CDC16↓, CUL4B↑, CBP↑, TSC2↑, HER2/EBBR2↓, BCR↓, TumCCA↑, chemoPv↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

BCR↓, 1,   CDC16↓, 1,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   cMyc↓, 1,  

Cell Death ⓘ

CBP↑, 1,  

Kinase & Signal Transduction ⓘ

CDC7↓, 1,   HER2/EBBR2↓, 1,   TSC2↑, 1,  

DNA Damage & Repair ⓘ

BRCA1↑, 1,   CUL4B↑, 1,   P53↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   cycF↓, 1,   E2Fs↓, 1,   P21↑, 1,   RB1↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

cDC2↓, 1,   EP300↑, 1,   NF2↑, 1,   PTEN↑, 1,  

Migration ⓘ

CDK4/6↓, 1,   MSH2↑, 1,   TSC1↑, 1,  

Clinical Biomarkers ⓘ

BRCA1↑, 1,   HER2/EBBR2↓, 1,  

Functional Outcomes ⓘ

chemoPv↑, 1,   TGFβR1↑, 1,  
Total Targets: 31

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: EP300, E1A binding protein p300
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:101  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page